# KEYNOTE-775 (NCT03517449)

> Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03517449
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Eisai Inc.
- Conditions: Endometrial Neoplasms
- Interventions: Pembrolizumab; Lenvatinib; Paclitaxel; Doxorubicin
- Enrollment: 827
- Primary outcome: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants
- Primary outcome: PFS Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on BICR in All-comer Participants
- Primary outcome: Overall Survival (OS) in pMMR Participants
- Primary outcome: OS in All-comer Participants

## Indexed commentary on KEYNOTE-775 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 36
- Podcasts: 36
- X threads: 11
- Bluesky threads: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-775-nct03517449

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03517449", "email": "<work email>"}; the inbox owner confirms by the emailed link.